Role of triglyceride-rich lipoproteins in diabetic nephropathy

被引:113
|
作者
Rutledge, John C. [1 ]
Ng, Kit F. [1 ]
Aung, Hnin H. [1 ]
Wilson, Dennis W. [2 ]
机构
[1] Univ Calif Davis, Sch Med, Div Cardiovasc Med, Davis, CA 95616 USA
[2] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA
关键词
LOW-DENSITY-LIPOPROTEIN; GROWTH-FACTOR-BETA; GLYCATION END-PRODUCTS; ENDOTHELIAL-CELL GLYCOCALYX; CORONARY-HEART-DISEASE; RENAL-DISEASE; TGF-BETA; APOLIPOPROTEIN(A) LEVELS; LIPOLYSIS PRODUCTS; METABOLIC SYNDROME;
D O I
10.1038/nrneph.2010.59
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Diabetic nephropathy is an increasingly important cause of morbidity and mortality worldwide. A large body of evidence suggests that dyslipidemia has an important role in the progression of kidney disease in patients with diabetes. Lipids may induce renal injury by stimulating TGF-beta, thereby inducing the production of reactive oxygen species and causing damage to the glomeruli and glomerular glycocalyx. Findings from basic and clinical studies strongly suggest that excess amounts of a variety of lipoproteins and lipids worsens diabetes-associated microvascular and macrovascular disease, increases glomerular injury, increases tubulointerstitial fibrosis, and accelerates the progression of diabetic nephropathy. The increasing prevalence of obesity, type 2 diabetes mellitus, and diabetic nephropathy means that interventions that can interrupt the pathophysiological cascade of events induced by lipoproteins and lipids could enable major life and cost savings. This Review discusses the structural, cellular, and microscopic findings associated with diabetic nephropathy and the influence of lipoproteins, specifically triglyceride-rich lipoproteins (TGRLs), on the development and perpetuation of diabetic nephropathy. Some of the accepted and hypothesized mechanisms of renal injury relating to TGRLs are also described.
引用
收藏
页码:361 / 370
页数:10
相关论文
共 50 条
  • [21] Triglyceride-rich lipoproteins and cardiovascular diseases
    Xu, Dandan
    Xie, Lin
    Cheng, Cheng
    Xue, Fei
    Sun, Chaonan
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [22] Triglyceride-rich lipoproteins and vascular function
    Haynes, WG
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) : 153 - 155
  • [23] The clinical case for triglyceride-rich lipoproteins
    Thompson, GR
    [J]. ATHEROSCLEROSIS XI, 1998, 1155 : 599 - 603
  • [24] Intracellular metabolism of triglyceride-rich lipoproteins
    Heeren, J
    Beisiegel, U
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2001, 12 (03) : 255 - 260
  • [25] Triglyceride-rich lipoproteins and progression of atherosclerosis
    Hodis, HN
    Mack, WJ
    [J]. EUROPEAN HEART JOURNAL, 1998, 19 : A40 - A44
  • [26] Leukocyte activation by triglyceride-rich lipoproteins
    Alipour, Arash
    van Oostrom, Antonie J. H. H. M.
    Izraeljan, Alisa
    Verseyden, Caroline
    Collins, Jennifer M.
    Frayn, Keith N.
    Plokker, Thijs W. M.
    Elte, Jan Willem F.
    Cabezas, Manuel Castro
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (04) : 792 - 797
  • [27] Cellular catabolism of triglyceride-rich lipoproteins
    Heeren, J
    Beisiegel, U
    [J]. ATHEROSCLEROSIS XI, 1998, 1155 : 873 - 878
  • [28] Are triglyceride-rich lipoproteins directly proatherogenic?
    Steinberg, D
    [J]. ATHEROSCLEROSIS, 1998, 138 : S5 - S5
  • [29] LP(A) AND PLASMA TRIGLYCERIDE-RICH LIPOPROTEINS
    MCCONATHY, WJ
    TRIEU, VN
    KLOR, HU
    CORDER, CN
    [J]. KLINISCHE WOCHENSCHRIFT, 1990, 68 : 117 - 119
  • [30] Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia
    Winkler, K
    Wetzka, B
    Hoffmann, MM
    Friedrich, I
    Kinner, M
    Baumstark, MW
    Zahradnik, HP
    Wieland, H
    März, W
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (03): : 1162 - 1166